1. 2) World Health Organization. “Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Proposed replacement of TRS 878, Annex 1.”: ‹http://www.who.int/biologicals/BS2132-CS_Recommendations_CLEAN_19_July_2010.pdf›, cited 19 July, 2010.
2. 3) Müller FJ, Goldmann J, Löser P, Loring JF. A call to standardize teratoma assays used to define human pluripotent cell lines. Cell Stem Cell, 6, 412–414 (2010).
3. 5) World Health Organization. “Requirements for the use of animal cells as in vitro substrates for the production of biologicals. WHO Technical Report Series No.878, Annex 1.”: ‹http://whglibdoc.who.int/trs/WHO_TRS_878.pdf›, cited 1998.
4. Primary Bioassay of Human Tumor Stem Cells
5. 7) Lewis AM. “Regulatory Implications of Neoplastic Cell Substrate Tumorigenicity.”: ‹http://www.fda.gov/ohrms/dockets/ac/05/slides/5-4188S1_2.ppt›, cited 2005.